Codexis offers asymmetric ECO platform upside at 2.5x EV/Sales, but permitting, dilution, and sustained losses make CDXS a speculative execution bet.
Overview
Codexis (CDXS) is a specialized enzyme-engineering company with product revenue from engineered biocatalysts and R&D revenue from technology transfers, licensing, and co-development. Its strategic pivot is toward ECO Synthesis, an enzymatic alternative to solid-phase oligonucleotide synthesis for scalable siRNA manufacturing. **The central investment case is that rapidly growing product revenue and ECO adoption can replace volatile technology-transfer revenue and create a higher-quality platform business.** In Q2 2026, total revenue was $14.92 million, down 2.6% year over year because R&D revenue fell to $1.70 million as the $37.8 million Merck agreement wound down. Product revenue nevertheless rose 79.1% to $13.22 million, while product gross margin reached 73.3%. The net loss narrowed to $12.01 million, or -$0.13 per share, and revenue and adjusted EPS exceeded consensus. A July offering raised $23.1 million net, increasing pro-forma cash to approximately $79.8 million and extending runway through the end of 2028. Valuation is depressed at approximately 1.9x trailing EV/sales versus 7.2x for biotechnology platform peers. Catalysts include ECO GMP permitting in H2 2026, an additional CDMO partnership targeted by year-end, and FDA Emerging Technologies engagement in Q4 2026. The principal trade-off is substantial execution, dilution, and profitability risk.